In this episode Dr. Gillian Beauchamp sits down with Dr. Matthew Salzman discusses the complications associated with the use of illicit fentanyl containing xylazine from wounds to withdrawal. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Alan Wolfe to discuss the possible clinical effects of  POPs (Persistent Organic Pollutants) and PFAS (Per and polyfluoroalkyl substances). 

In this episode Dr. Gillian Beauchamp sits down with Dr. Travis Olives to discuss gap junctions and cardiac effects of bupropion toxicity. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Stephanie Weiss to discuss HERG channel blockade, QTc prolongation and cardiotoxicity. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Meghan Spyres to discuss the evolution of antivenom treatment of North American Pit Viper envenomation with specific discussion of the differences between Fab (CroFab) and F(ab)2 (ANAVIP) antivenom. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Christian Tomaszewski to discuss risk factors for delayed cardiomyopathy and mortality after carbon monoxide exposure. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Alex Manini to discuss single nucleotide polymorphisms (SNPs) of the Mu receptor and how they may relate to overdose severity of opioid overdose. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Fiona Garlich to discuss mechanisms and clinical presentations of aconitine, veratrum alkaloid and grayanotoxin cardiotoxicity. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Robert Haley to discuss Gulf War Illness and what caused over 100,000 people to become ill during and after the Gulf War. Dr. Haley describes the gene-environment interaction between PON-1 polymorphism and exposure to sarin gas. 

In this episode Dr. Gillian Beauchamp sits down with Dr. Spencer Greene to discuss his recent case series of antimuscarninic delirium treated with rivastigmine in the setting of physostigmine shortages.